By JT Santana | jtwb768

For thousands of people who lived through the first decades of AIDS, old age was never part of the plan. Antiretroviral therapy changed that future. Medicine learned how to keep HIV from destroying the immune system, transforming a frequently fatal infection into a manageable chronic condition for people with access to effective treatment. Survival, however, created a question the early epidemic rarely had the luxury to ask: What happens when people live with HIV for 20, 30, 40, or 50 years?

The Future That Was Never Supposed to Arrive

There is something almost surreal about National HIV/AIDS and Aging Awareness Day.

More than four decades after the first recognized U.S. AIDS cases appeared in federal surveillance reports, the country now has an HIV population in which older adults are no longer unusual. HIV.gov reports that approximately 54% of people living with diagnosed HIV in the United States in 2023 were age 50 or older, representing 597,296 people. CDC’s newer 2024 surveillance release counted 1,158,701 people living with diagnosed HIV across the United States and seven territories and freely associated states; the single largest age group was 55 through 64, with 300,819 people (Centers for Disease Control and Prevention [CDC], 2026; HIV.gov, n.d.). (HIV.gov)

Those numbers represent one of the most dramatic reversals in modern medicine.

During the early AIDS epidemic, aging was not a serious clinical planning problem for many people with AIDS. Survival itself was uncertain. HIV.gov notes that, before effective therapy, people diagnosed with AIDS could sometimes expect only one or two years of survival following diagnosis. The central questions were immediate and brutal: Could Pneumocystis pneumonia be treated? Would Kaposi sarcoma progress? Would another opportunistic infection appear? Was there an experimental drug worth trying? Would a person live long enough to see the next treatment become available? (HIV.gov)

Modern antiretroviral therapy rewrote those questions.

The transformation is so profound that its success can obscure the medical and social reality now emerging behind it. Viral suppression does not freeze a body at the age treatment began. It does not erase earlier immune damage. It does not reverse every toxic exposure associated with older generations of HIV medications. It does not prevent ordinary aging. It does not erase smoking histories, poverty, trauma, racism, homophobia, sexism, substance use, unstable housing, food insecurity, social isolation, or decades of chronic stress.

An older person living with HIV may now face hypertension, coronary artery disease, osteoporosis, kidney disease, diabetes, cancer screening, cognitive changes, depression, frailty, chronic pain, medication interactions, reduced mobility, or the loss of a social network built during an epidemic that already took too many people.

That is the paradox at the center of HIV and aging.

We succeeded in keeping people alive.

Now health systems have to decide what surviving is supposed to look like.

Survival Changed the Medical Question

For much of the early epidemic, the clinical target was straightforward in the most terrible sense: prevent death.

Combination antiretroviral therapy changed the target. Viral suppression became achievable for millions of people, and treatment could prevent the progressive immune destruction that had defined AIDS. Effective treatment now permits many people with HIV to live long lives, particularly when infection is diagnosed early, treatment begins quickly, viral suppression is sustained, and other health conditions receive appropriate care (National Institutes of Health [NIH], 2026). (HIVinfo)

The success can be measured through programs such as the Ryan White HIV/AIDS Program. In 2024, the program served 601,853 people. Among clients receiving HIV medical care, 91.4% achieved viral suppression. Nearly half of all Ryan White clients, 47.4%, were age 50 or older, and 13.4% were at least 65. In 2020, clients age 65 and older accounted for 9.5% of the program population, making the shift over only four years striking (Health Resources and Services Administration [HRSA], 2025). (Ryan White HIV/AIDS Program)

Viral suppression, however, is not the same thing as complete health.

Federal HIV treatment guidelines now devote substantial attention to older adults for precisely that reason. Older people with HIV may face cardiovascular disease, chronic kidney disease, osteoporosis, fragility fractures, liver disease, metabolic disorders, neurocognitive changes, cancers, frailty, depression, and medication-related complications. NIH guidance states that the burden of age-associated disease is higher among people with HIV than among the general population and calls for coordination among HIV specialists, primary-care clinicians, geriatric specialists, and other providers (Panel on Antiretroviral Guidelines for Adults and Adolescents, 2024). (Clinical Info)

That does not mean HIV causes every illness experienced by an older person living with the virus.

The picture is far more complicated. Age itself contributes to disease. Traditional cardiovascular risk factors remain relevant. Smoking, alcohol use, physical activity, nutrition, genetics, socioeconomic conditions, access to preventive medicine, previous infections, hormonal changes, and other chronic illnesses all affect later-life health. HIV adds another layer through chronic immune activation, inflammation, past periods of uncontrolled viral replication, treatment exposure, and interactions among existing conditions.

Older long-term survivors may carry a further historical burden.

Some were treated during eras when HIV therapy was far more toxic than current regimens. Early antiretroviral combinations saved lives, yet certain drugs were associated with substantial metabolic, renal, neurologic, mitochondrial, gastrointestinal, and body-composition effects. Some survivors cycled through complicated regimens, treatment failures, resistance, opportunistic infections, experimental medications, or periods when available treatment simply could not suppress their virus.

That history is written into bodies that are now entering their 60s, 70s, and 80s.

Aging with HIV is not a single medical condition. It is the intersection of ordinary aging, HIV biology, treatment history, personal health history, and the social conditions in which survival occurred.

The bill is rarely one invoice.

It arrives as a stack.

The Heart, the Bones, the Kidneys, and the Brain

Cardiovascular disease offers one of the clearest examples of how HIV medicine has changed.

NIH treatment guidelines report that people with HIV have about twice the risk of atherosclerotic cardiovascular disease compared with people without HIV, with cardiovascular disease often appearing at younger ages. Traditional risk factors explain part of that difference. Persistent inflammation and immune activation appear to contribute as well, including among people whose HIV remains virally suppressed (Panel on Antiretroviral Guidelines for Adults and Adolescents, 2024). (Clinical Info)

The REPRIEVE trial demonstrated how seriously HIV medicine now takes this problem. Researchers enrolled 7,769 adults with HIV who were receiving antiretroviral therapy and had low-to-moderate traditional cardiovascular risk. Participants receiving pitavastatin experienced a 35% lower risk of major cardiovascular events than participants receiving placebo. The trial was stopped early after an interim analysis showed sufficient evidence of benefit. Those results helped produce new federal recommendations on statin therapy for many people with HIV between ages 40 and 75 (Grinspoon et al., 2023). (New England Journal of Medicine)

That finding is revealing in two ways.

The first is encouraging: HIV-specific research can identify interventions capable of preventing illnesses that increasingly shape long-term survival. The second is more sobering: keeping HIV itself suppressed does not eliminate every excess health risk associated with living with the infection.

Bone health presents another example. NIH reports a clear association among HIV infection, certain antiretroviral drugs, and bone loss. Federal treatment guidance cites evidence suggesting that people with HIV have approximately a 1.5-fold greater risk of fragility fracture and a substantially elevated risk of hip fracture compared with people without HIV. Men age 50 and older and postmenopausal women with HIV warrant particular attention to bone health and fracture risk (NIH, 2024; Panel on Antiretroviral Guidelines for Adults and Adolescents, 2024). (HIVinfo)

Kidney disease creates a similar intersection. HIV itself can affect renal function. Some antiretroviral drugs require renal monitoring or dose adjustment. Diabetes, hypertension, vascular disease, age, and other medications can add risk. An older person with HIV may need clinicians to make treatment decisions across several medical domains at once rather than treating HIV as an isolated infection.

Then comes cognitive health.

NIH guidelines state that age-related decline on neuropsychological testing can be steeper among people with HIV than among people without HIV. Cognitive symptoms can involve memory, attention, processing speed, executive function, or motor skills. The causes are frequently multifactorial and may involve vascular disease, mood disorders, medication effects, sleep disorders, substance use, social isolation, chronic inflammation, or neurodegenerative illness alongside HIV-related factors (Panel on Antiretroviral Guidelines for Adults and Adolescents, 2024). (Clinical Info)

That nuance is important. Memory problems in an older person with HIV should not automatically be labeled HIV-associated neurocognitive disorder. A clinician has to consider depression, thyroid disease, vitamin deficiencies, syphilis, sleep apnea, hearing loss, cerebrovascular disease, medication effects, Alzheimer disease, and other treatable or progressive conditions.

The shift represents a kind of medical maturity in HIV care.

The question is no longer simply, “Is the virus suppressed?”

The better question is, “How is the person doing?”

Polypharmacy: When Survival Comes in a Pill Organizer

One of the strangest symbols of progress in HIV medicine may be the pill organizer.

People who remember taking complicated early HIV regimens may now take a single antiretroviral tablet or receive long-acting treatment. Yet the total medication burden can rise again with age. A person may take HIV treatment in combination with drugs for blood pressure, cholesterol, diabetes, pain, sleep, depression, anxiety, reflux, osteoporosis, neuropathy, prostate disease, menopause symptoms, kidney disease, anticoagulation, or other conditions.

Supplements and over-the-counter products add another layer.

Federal HIV guidelines identify polypharmacy as a major concern for older adults. Drug interactions can occur between antiretroviral medications and statins, anticoagulants, anticonvulsants, psychiatric drugs, acid-suppressing medications, supplements, herbal preparations, and other therapies. Age-related changes in kidney and liver function can alter how medications are processed, making regular medication review increasingly significant (Panel on Antiretroviral Guidelines for Adults and Adolescents, 2024). (Clinical Info)

Polypharmacy carries consequences far beyond inconvenience.

Medication interactions can contribute to falls, fractures, delirium, hospitalization, treatment nonadherence, dosing errors, additive toxicity, and cognitive problems. NIH treatment guidance cites research from the Swiss HIV Cohort Study in which polypharmacy was present in 66% of participants with HIV age 75 and older, with inappropriate prescribing identified at a similar rate. That study does not automatically describe the entire U.S. population, yet it illustrates the scale of medication management that geriatric HIV care can require. (Clinical Info)

The clinical response cannot consist of adding another prescription every time another diagnosis appears.

Deprescribing becomes part of care. Medication reconciliation becomes part of HIV medicine. Pharmacists become essential members of the treatment team. HIV specialists need communication from cardiologists, oncologists, psychiatrists, endocrinologists, neurologists, nephrologists, and primary-care providers.

A person aging with HIV should not have to function as the only information system connecting six specialists.

This is where the current structure of American health care can work against the patient. HIV medicine historically developed highly specialized systems, in part from necessity. Those systems became extraordinarily successful at viral suppression. Geriatric medicine operates from a different model, one focused on function, mobility, cognition, medications, falls, social support, goals of care, and multiple chronic illnesses.

Older people with HIV increasingly need both.

The next generation of HIV care cannot treat geriatric medicine as an optional referral made only after something goes wrong.

It needs to become part of the architecture.

Long-Term Survivor Is Not Another Word for Older

The language surrounding HIV and aging requires care.

“People age 50 and older with HIV” describes an age group. “Long-term survivor” describes a history, and no single definition has universal acceptance. Some organizations use the term for people diagnosed before effective combination antiretroviral therapy became available in 1996. Some research uses a duration threshold, such as living with HIV for more than ten years. Lifetime survivors who acquired HIV perinatally or during childhood bring another history entirely.

The groups overlap, but they are not interchangeable.

A 68-year-old person diagnosed with HIV last year is an older adult with HIV but may not identify as a long-term survivor. A 45-year-old who acquired HIV at birth may have lived with the virus longer than someone twice that person’s age. A 62-year-old diagnosed in 1987 may have experienced AZT monotherapy, opportunistic infections, early drug trials, friends dying weekly, treatment resistance, and years spent assuming retirement would never be relevant.

The medical histories differ.

So do the psychological histories.

A 2025 qualitative study by Ahmed and colleagues interviewed 32 U.S. long-term survivors ages 60 through 82. Participants had lived an average of more than three decades after diagnosis. Their priorities extended far beyond viral suppression. They described cardiovascular disease, cognitive concerns, kidney health, bone health, diabetes, safer long-term treatment, financial stability, housing, mental health, social connection, and a desire for health systems capable of treating the whole person rather than HIV in isolation (Ahmed et al., 2025). (PubMed Central (PMC))

The study was small and qualitative, so its findings should not be treated as national prevalence estimates. Its value lies elsewhere. It records what happens when researchers ask survivors what they need rather than deciding that an undetectable viral load answers the question.

One participant described a reality that appears repeatedly across aging-HIV research: HIV is no longer the only health problem.

That shift is medicine’s success story and medicine’s new assignment.

The epidemic created a generation that fought to gain access to treatment. Some members of that generation now have to fight for geriatric care capable of recognizing the consequences of having survived.

The Mental Health Bill Never Disappeared

There is no laboratory test for surviving everyone you knew.

There is no viral-load assay for the memory of hospital rooms, memorial services, funerals, rejection, public hostility, or the years when an HIV diagnosis could alter employment, housing, relationships, insurance, family ties, and the expectation of having a future.

Long-term survival can carry grief that ordinary clinical metrics rarely capture.

Ahmed and colleagues found that older long-term survivors identified depression, anxiety, survivor guilt, and unresolved psychological effects of the epidemic among their major concerns. Participants described decades of advocacy shaped by losing partners, friends, and community members. Some expressed a fear that health systems were forgetting long-term survivors just as their needs were becoming more complicated (Ahmed et al., 2025). (PubMed Central (PMC))

Federal HIV guidelines recognize depression and anxiety as significant issues among older people with HIV and recommend mental-health screening and appropriate treatment. Cognitive changes can make that work harder since depression, medication effects, vascular illness, chronic pain, sleep problems, grief, and neurocognitive disease may overlap in ways that are difficult to separate (Panel on Antiretroviral Guidelines for Adults and Adolescents, 2024). (Clinical Info)

Social isolation can compound the problem.

A systematic review of medicine management and support needs among older people with HIV found recurring concerns related to loneliness, low social support, stigma, and isolation. Some studies included in that review reported remarkably high levels of loneliness or weak support networks among older participants, though the studies varied in populations, methods, and geography (Kiplagat et al., 2023). (PubMed Central (PMC))

For LGBTQ long-term survivors, ordinary aging may intersect with another demographic reality: the social networks on which older people traditionally rely may look different.

Some never married. Some had relationships that were never legally recognized. Some lost partners long before marriage equality existed. Some are estranged from biological relatives. Some spent decades building chosen families, then watched AIDS cut through those families. Some now reach old age without adult children, spouses, siblings, or nearby caregivers available to provide the informal labor on which the American elder-care system heavily depends.

Women aging with HIV may carry different histories involving caregiving, poverty, racial disparities, gender-based violence, later diagnosis, and years spent outside the public image of an epidemic too often presented as exclusively male.

Black and Latino long-term survivors may face the cumulative effects of racial inequity alongside HIV stigma and aging.

People who acquired HIV through injection drug use may contend with criminalization histories, hepatitis, unstable housing, or substance-use treatment systems.

Transgender older adults with HIV may encounter health systems that remain poorly prepared for aging, HIV care, and gender-affirming care in the same patient.

There is no single long-term-survivor story.

That is precisely why a medical model centered almost entirely on viral suppression is no longer enough.

Poverty Ages Too

The financial history of long-term HIV survival receives far less attention than the pharmacology.

Many people diagnosed during the 1980s or early 1990s had little reason to expect a normal lifespan. Some left careers after becoming sick. Some went onto disability. Some depleted savings. Some lost jobs through discrimination or illness. Some never accumulated retirement assets. Some survived years when private insurance could be difficult or impossible to obtain. Some entered adulthood expecting to die young and made financial decisions inside that expectation.

Then treatment worked.

A person who financially planned for five years can find himself alive 30 years later.

That is a victory with economic consequences.

The 2025 Ahmed study identified housing, food security, health-care access, and financial stability among major concerns expressed by long-term survivors. Federal treatment guidance similarly recognizes health-care costs, employment loss, copayments, deductibles, and other financial pressures as factors that can disrupt treatment (Ahmed et al., 2025; Panel on Antiretroviral Guidelines for Adults and Adolescents, 2024). (PubMed Central (PMC))

The Ryan White HIV/AIDS Program remains one of the most significant pieces of the U.S. response. In 2024 it served more than 600,000 people, more than half of the population living with diagnosed HIV in the country. Its services extend beyond antiretroviral medication into medical care and support services that help people remain connected to treatment (HRSA, 2025). (HRSA)

Its aging client population raises an unavoidable policy question.

What does an HIV safety-net program look like when nearly half of its clients are over 50 and a growing share are over 65?

The answer cannot stop at providing antiretroviral drugs.

An aging population needs transportation, nutrition, dental care, mental-health services, housing assistance, medication management, home-based support, mobility services, caregiver resources, cancer screening, fall prevention, geriatric assessment, social connection, and help coordinating Medicare, Medicaid, Ryan White services, prescription coverage, and local aging programs.

HIV policy spent decades learning how to prevent premature death.

It now has to learn how to support later life.

Older Adults Still Acquire HIV

The aging-HIV conversation can create another misconception if it focuses exclusively on people who have lived with HIV for decades.

People acquire HIV after age 50.

People acquire HIV after age 60.

People acquire HIV after age 70.

Sexuality does not retire when someone receives an AARP card.

CDC’s 2024 data demonstrate a persistent problem with later diagnosis among older adults. Among people age 65 and older diagnosed with HIV in 2024, 35.5% received a simultaneous stage 3, or AIDS, classification. That was the highest percentage of any age group. Late diagnosis means lost time during which treatment could have protected immune function and prevented transmission (CDC, 2026). (CDC)

Several factors may contribute.

Clinicians may be less likely to offer HIV testing to older adults. Patients may underestimate their own risk. Sexual-health discussions can disappear from medical visits once a patient reaches a certain age. Symptoms associated with HIV may be attributed to aging or another chronic condition. Older adults may have received decades of cultural messaging suggesting HIV belongs primarily to younger gay men or people who inject drugs.

That stereotype is medically dangerous.

Older adults have sex. Older adults date after divorce or widowhood. Older gay and bisexual men enter new relationships. Older heterosexual adults can acquire HIV. Older transgender people can acquire HIV. Condom use may decline after pregnancy prevention ceases to be a concern.

Prevention has to age along with the population.

That includes routine testing when clinically appropriate, discussion of sexual health without embarrassment, access to pre-exposure prophylaxis, accurate information about post-exposure prophylaxis, and recognition that prevention campaigns featuring only young adults can accidentally tell older people that HIV no longer concerns them.

Aging with HIV involves two populations at once: people who survived long enough to grow older with the virus and people who acquire HIV after they are already older.

Both deserve to be visible.

Viral Suppression Was a Finish Line. It Has Become the Starting Line.

The extraordinary success of HIV treatment created a strange policy problem: the better medicine became at preventing AIDS deaths, the easier it became for the broader public to assume the epidemic had been solved.

It has not.

At the individual level, an undetectable viral load is an extraordinary achievement. Effective antiretroviral treatment protects health, preserves immune function, and prevents sexual transmission when viral suppression is maintained. U=U—Undetectable Equals Untransmittable—changed the medical and social meaning of HIV.

Yet viral suppression tells us almost nothing about whether a person has stable housing.

It does not tell us whether a 70-year-old long-term survivor is lonely.

It does not tell us whether he can afford his cardiovascular medications.

It does not tell us whether she has osteoporosis.

It does not tell us whether a patient can remember a complicated medication schedule.

It does not tell us whether someone has transportation to three specialists.

It does not tell us whether the person spent 30 years expecting to die and now has no retirement savings.

It does not tell us whether survivor grief returns every time another friend dies.

The next era of HIV medicine requires a broader definition of success.

A patient who is virally suppressed but falling repeatedly at home needs more than excellent infectious-disease care. A patient with an undetectable viral load and untreated depression is not receiving complete care. A patient whose HIV is perfectly controlled but who cannot afford rent remains medically vulnerable.

The Ryan White program’s 91.4% viral suppression rate among clients receiving HIV medical care is a remarkable public-health achievement. (HRSA) The challenge now is extending that same ambition to healthy aging.

Can people with HIV remain mobile?

Can they preserve cognition?

Can they prevent avoidable cardiovascular disease?

Can they receive cancer screening?

Can clinicians reduce unnecessary medication burden?

Can people remain housed?

Can they age with social connection?

Can they find caregivers?

Can they afford to live as long as medicine has enabled them to live?

Those are HIV questions now.

We Asked People to Survive. We Owe Them More Than Survival.

There is a photograph somewhere from the early epidemic of almost every long-term survivor at an age they never expected to outlive.

Perhaps it shows a young man in 1987 standing beside friends who are gone.

Perhaps it shows a woman diagnosed when public campaigns barely acknowledged women with HIV.

Perhaps it shows an activist marching for medication access, never imagining that decades later the fight would involve Medicare formularies, bone-density scans, statins, home health aides, or finding a geriatrician who knows HIV.

Perhaps there is no photograph at all.

The historical record of AIDS is filled with absence.

National HIV/AIDS and Aging Awareness Day asks us to look at the people who remain.

They are evidence of what science accomplished. Modern antiretroviral therapy ranks among the great achievements of medicine. HIV went from an infection associated with catastrophic immune destruction and mass premature death to a chronic condition that many people can manage across decades.

The victory deserves celebration.

It deserves something more demanding, too.

It requires acknowledging that medicine extended life faster than many health systems prepared for the lives being extended.

It requires acknowledging that long-term survivors may enter old age carrying earlier treatment toxicities, resistance histories, grief, financial insecurity, and decades of stigma.

It requires recognizing that an aging HIV population needs cardiology, oncology, geriatrics, psychiatry, neurology, nephrology, pharmacy, social work, housing assistance, nutrition services, and community connection alongside infectious-disease expertise.

It requires remembering that age 50 and “long-term survivor” are not synonyms.

It requires testing older adults who remain sexually active rather than assuming HIV risk disappears with gray hair.

It requires research that does not exclude older people from the very studies meant to improve their future.

It requires a public-health system willing to measure quality of life with some of the same seriousness it once used to measure viral load and CD4 counts.

Forty-five years ago, the country was trying to identify why young people were dying.

Today, hundreds of thousands of people with diagnosed HIV in the United States are over 50.

That sentence is astonishing.

Some survived the years before combination therapy. Some were diagnosed after treatment had transformed HIV care. Some acquired HIV later in life. Some have carried the virus since childhood. Their histories are different, yet together they demonstrate what happens when research, activism, clinical care, public funding, and human persistence turn an almost unthinkable future into an ordinary demographic fact.

People with HIV grew old.

Now medicine, public health, policymakers, service organizations, families, and communities have to be ready for what that victory requires.

We spent decades trying to give people with HIV more years.

The next measure of success is what those years contain.

References

Ahmed, A., Taylor, J., Lai, J. C.-J., Lau, R., Diunugala, S. D., Louella, M., Brown, B., Nguyen, A. L., Karris, M., Dee, L., Berry, J., & Dubé, K. (2025). “It’s not just HIV anymore”: A qualitative exploration of health, research, community and mental health priorities of long-term survivors of HIV in the United States. AIDS Care, 38(3), 506–520. https://doi.org/10.1080/09540121.2025.2584603

Centers for Disease Control and Prevention. (2026). HIV diagnoses, deaths, and prevalence—United States and 7 territories and freely associated states, 2024.

Grinspoon, S. K., Fitch, K. V., Zanni, M. V., Fichtenbaum, C. J., Umbleja, T., Aberg, J. A., Overton, E. T., Malvestutto, C. D., Bloomfield, G. S., Currier, J. S., Martinez, E., Roa, J. C., Diggs, M. R., Fulda, E. S., Paradis, K., Wiviott, S. D., Foldyna, B., Looby, S. E., Desvigne-Nickens, P., . . . Douglas, P. S. (2023). Pitavastatin to prevent cardiovascular disease in HIV infection. The New England Journal of Medicine, 389, 687–699. https://doi.org/10.1056/NEJMoa2304146

Health Resources and Services Administration. (2025). Ryan White HIV/AIDS Program annual client-level data report 2024. U.S. Department of Health and Human Services.

HIV.gov. (n.d.). Aging with HIV. U.S. Department of Health and Human Services.

Kiplagat, J., et al. (2023). Ageing with HIV: Medicine optimisation challenges and support needs for older people living with HIV: A systematic review. Journal of Clinical Medicine, 12, 274.

National Institutes of Health. (2024). HIV and osteoporosis. HIVinfo.

National Institutes of Health. (2026). HIV and older people. HIVinfo.

Panel on Antiretroviral Guidelines for Adults and Adolescents. (2024). Guidelines for the use of antiretroviral agents in adults and adolescents with HIV: HIV and the older person. Department of Health and Human Services.